Precision Bio aufwärts mit neuer WKN
Seite 1 von 1 Neuester Beitrag: 09.01.25 17:41 | ||||
| Eröffnet am: | 14.02.24 20:50 | von: moneywork4. | Anzahl Beiträge: | 25 |
| Neuester Beitrag: | 09.01.25 17:41 | von: Balu4u | Leser gesamt: | 7.329 |
| Forum: | Hot-Stocks | Leser heute: | 3 | |
| Bewertet mit: |  | |||
Selten genug dass eine Aktie nach Resplit aufwärts geht, hoffe das bleibt so
https://www.nasdaq.com/de/market-activity/stocks/dtil/real-time
https://www.finanznachrichten.de/...ien/precision-biosciences-inc.htm
https://precisionbiosciences.com/
https://www.nasdaq.com/de/market-activity/stocks/dtil/real-time
https://www.finanznachrichten.de/...ien/precision-biosciences-inc.htm
https://precisionbiosciences.com/
Optionen
| Boardmail an "Balu4u" |
Wertpapier: Precision BioSciences I |
Darum ging es hoch ..
https://www.nasdaq.com/articles/...agreement-with-caribou-biosciences
https://www.nasdaq.com/articles/...agreement-with-caribou-biosciences
Optionen
| Boardmail an "Balu4u" |
Wertpapier: Precision BioSciences I |
einer, warum man die in Deutschland noch nicht handeln kann. Der Split ist schon paar Tage her oder dauert dass hier länger ???
Hab mal geschaut. FRA letzter Handelstag, aber auf Xetra sollte sie wieder handelbar sein was aktuell nicht der Fall ist. Aber wenigstens stimmt die Richtung
Optionen
| Boardmail an "Balu4u" |
Wertpapier: Precision BioSciences I |
Optionen
| Boardmail an "Balu4u" |
Wertpapier: Precision BioSciences I |
Die Kurzziele wurden auch umgestellt
https://www.nasdaq.com/market-activity/stocks/dtil/analyst-research
https://www.nasdaq.com/market-activity/stocks/dtil/analyst-research
Optionen
| Boardmail an "Balu4u" |
Wertpapier: Precision BioSciences I |
müssten heute eigentlich Explodieren, Wahnsinns Zahlen. Bis jetzt aber ziemlich ruhig im Pre-Handel. Schauen wir mal ... Precision BioSciences GAAP EPS of $4.70 beats by $6.32, revenue of $49.9M beats by $41.58M
aktuell alle abverkauft. Erwarte nach Weihnachten/ Neujahr eine Erholung. Da werden die Karten sicherlich neu gemischt. Hat vielleicht etwas mit der Steuer oder Verlustrechnung zu tun...
Optionen
| Boardmail an "Balu4u" |
Wertpapier: Precision BioSciences I |
Den anderen bestimmt. Aber der Verfall hier ist schon enorm. Über 50% in 3 Monaten. Auf der anderen Seite, bei den wenigen Stücken am Markt, könnte es eine 300-400% Rakete werden bei positiven Nachrichten. ..aber so'n Boden, dürften wir trotzdem mal bald gerne sehen......
nützt ja nichts, wenn wir bis auf 1,00,- fallen und dann 300 - 400% machen.. ..sieht heute im Pre-Markt auch nicht viel besser aus......
Optionen
| Boardmail an "Balu4u" |
Wertpapier: Precision BioSciences I |
Ob Kursrelevant ?? ..Mal schauen... Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B
- Approval in Hong Kong marks the first clinical trial application clearance of an in vivo gene editing approach for chronic hepatitis B in Hong Kong and the second CTA approval for PBGENE-HBV in 2024
- ELIMINATE-B is a global, multi-site study now actively recruiting patients; expected to report clinical data as it matures throughout 2025
- U.S. investigational new drug (IND) anticipated in 2025
December 18, 2024 07:01 AM Eastern Standard Time
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that it has received Clinical Trial Application (CTA) approval in Hong Kong to study PBGENE-HBV in the ongoing ELIMINATE-B Phase I trial. PBGENE-HBV is Precision’s lead wholly owned in vivo gene editing program designed to cure chronic hepatitis B by eliminating cccDNA, the key source of replicating hepatitis B virus (HBV), and inactivating integrated HBV DNA in hepatocytes. The company is actively recruiting patients for the ELIMINATE-B trial in Moldova and has begun activating a top infectious disease clinical site in Hong Kong as part of its global regulatory and clinical operations strategy.
“We are pleased to receive our second CTA approval for PBGENE-HBV, expanding our ELIMINATE-B trial into a world-class HBV clinical trial site in Hong Kong”
Post this
“We are pleased to receive our second CTA approval for PBGENE-HBV, expanding our ELIMINATE-B trial into a world-class HBV clinical trial site in Hong Kong,” said Dr. Murray Abramson, Senior Vice President, Head of Clinical Development of Precision BioSciences. “PBGENE-HBV has been designed to target a viral site that is prevalent across all HBV genotypes, including in Asia, and we believe that this will enable us to evaluate and provide access to as many patients as possible. In addition to Hong Kong, our clinical trial site in Moldova continues to execute as planned, and we look forward to sharing clinical data as it matures throughout 2025.”
- Approval in Hong Kong marks the first clinical trial application clearance of an in vivo gene editing approach for chronic hepatitis B in Hong Kong and the second CTA approval for PBGENE-HBV in 2024
- ELIMINATE-B is a global, multi-site study now actively recruiting patients; expected to report clinical data as it matures throughout 2025
- U.S. investigational new drug (IND) anticipated in 2025
December 18, 2024 07:01 AM Eastern Standard Time
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that it has received Clinical Trial Application (CTA) approval in Hong Kong to study PBGENE-HBV in the ongoing ELIMINATE-B Phase I trial. PBGENE-HBV is Precision’s lead wholly owned in vivo gene editing program designed to cure chronic hepatitis B by eliminating cccDNA, the key source of replicating hepatitis B virus (HBV), and inactivating integrated HBV DNA in hepatocytes. The company is actively recruiting patients for the ELIMINATE-B trial in Moldova and has begun activating a top infectious disease clinical site in Hong Kong as part of its global regulatory and clinical operations strategy.
“We are pleased to receive our second CTA approval for PBGENE-HBV, expanding our ELIMINATE-B trial into a world-class HBV clinical trial site in Hong Kong”
Post this
“We are pleased to receive our second CTA approval for PBGENE-HBV, expanding our ELIMINATE-B trial into a world-class HBV clinical trial site in Hong Kong,” said Dr. Murray Abramson, Senior Vice President, Head of Clinical Development of Precision BioSciences. “PBGENE-HBV has been designed to target a viral site that is prevalent across all HBV genotypes, including in Asia, and we believe that this will enable us to evaluate and provide access to as many patients as possible. In addition to Hong Kong, our clinical trial site in Moldova continues to execute as planned, and we look forward to sharing clinical data as it matures throughout 2025.”
Bald unter 4 Dollar?
Überlege ein Limit bei 3,50 zu platzieren
https://www.nasdaq.com/market-activity/stocks/dtil
Überlege ein Limit bei 3,50 zu platzieren
https://www.nasdaq.com/market-activity/stocks/dtil
Optionen
| Boardmail an "Balu4u" |
Wertpapier: Precision BioSciences I |
die heute grün ist. Nach dem Absturz ist aber auch eine Erholung überfällig. Hoffe es ist mehr als ein Strohfeuer
https://www.nasdaq.com/market-activity/stocks/dtil
https://www.nasdaq.com/market-activity/stocks/dtil
Optionen
| Boardmail an "Balu4u" |
Wertpapier: Precision BioSciences I |
..iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency
First in vivo gene insertion clinical trial dosing infants reports complete clinical response in the first participant at the lowest dose level (1.3 x 1013 GC/kg) of ECUR-506 from three months post exposure to the end of study (six months post exposure) as demonstrated by the removal of standard of care ammonia scavenging medicines, followed by absence of hyperammonemic crises and normalization of protein intake
The OTC-HOPE Phase 1/2 trial has regulatory authorization in four geographies (US, UK, Spain and Australia) and is currently enrolling with the complete data readout anticipated in 1H 2026
ECUR-506 for neonatal onset OTC deficiency represents a meaningful potential clinical and commercial opportunity, affecting over 1,000 births per year globally
First in vivo gene insertion clinical trial dosing infants reports complete clinical response in the first participant at the lowest dose level (1.3 x 1013 GC/kg) of ECUR-506 from three months post exposure to the end of study (six months post exposure) as demonstrated by the removal of standard of care ammonia scavenging medicines, followed by absence of hyperammonemic crises and normalization of protein intake
The OTC-HOPE Phase 1/2 trial has regulatory authorization in four geographies (US, UK, Spain and Australia) and is currently enrolling with the complete data readout anticipated in 1H 2026
ECUR-506 for neonatal onset OTC deficiency represents a meaningful potential clinical and commercial opportunity, affecting over 1,000 births per year globally